20170825-中国银河国际证券-联邦制药-03933.HK-Insulin slowed down, 6-APA positives reflected. Maintain HOLD..pdf 20170828-中国银河国际证券-彩生活-01778.HK-Earnings improved but potential yet to be released: Maintain BUY.pdf 20170829-中国银河国际证券-成实外教育-01565.HK-Virscend Education Interim Results.pdf 20170828-中国银河国际证券-瑞声科技-02018.HK-Concerns about Q2 results put to rest. Optics business development will trigger a further re-rat 20170830-中国银河国际证券-上海实业控股-00363.HK-NEED MORE CONCRETE ACTION TO UNLOCK VALUE.pdf 20170830-中国银河国际证券-绿叶制药-02186.HK-Lipusu looking gloomy. Execution in doubt. Downgrade to SELL..pdf 20170829-中国银河国际证券-中信证券-06030.HK-Weak 1H17 Results Due to Unfavourable Market Conditions.pdf 20170822-中国银河国际证券-申洲国际-02313.HK-1H 2017 Results Presentation Key Takeaways. Vietnam operation will have a positive impact..pdf 20170830-中国银河国际证券-三生制药-01530.HK-Weaker-than-expected 1H17 results, but recovery expected. Maintain HOLD..pdf 20170901-招银国际-招财日报.pdf